RE:RE:sage adviceSage is a Boston are pharma with a CNS focused drug platform including a couple of approved depression drugs. They were in a development agreement with Biogen which is about to end, and now Biogen has made a hostile takeover bid. From Sage website:
"**Biogen terminated its rights as to the SAGE-324 program in September 2024; the termination will be effective on February 17, 2025."
So my question is about our shareholder group(s) control in such an event. I believe that there is a controlling group hiding within the list of major shareholders. It looks to me like the $2 financing price was set in stone before the 60:1 consolidation was decided, so the relevant question back then was how high a ratio was needed to gain sufficient control in all contingencies.